Dr. Tongqing Zhou is Chief and Senior Staff Scientist at the Structural Bioinformatics Section, Vaccine Research Center, NIAID, NIH. His research is mainly focused on structural basis of broadly neutralizing HIV-1 antibodies, antibody ontogeny that guide the development of broadly neutralizing antibodies, and structure-based design and testing of novel vaccines for HIV. Recently, Dr. Zhou’s research also expanded into other infectious diseases, such as RSV, Influenza, Zika, MERS and HCMV. Dr. Zhou has published more than 70 peer-reviewed research papers, including 19 in Nature, Science and Cell. He is a Clarivate Analytics (Thompson Reuters) Highly Cited Researcher in Microbiology in 2014, 2015,2017 and 2018. Dr. Zhou is co-inventor of several patents on potential HIV, RSV and HPIV vaccines and therapeutic antibodies, of which broadly neutralizing antibody N6 has been exclusively licensed, another antibody, VRC01, is in phase 2b trial. Dr. Zhou received B.S. in Biochemistry from Wuhan University, China, in 1989 and Ph.D. in Cell Biology from the Chinese Academy of Sciences in 1994. Before joining the VRC in September 2001, Dr. Zhou was a postdoctoral research associate at Wayne State University School of Medicine, where he obtained his x-ray crystallography training and M. S. in Electrical and Computer Controlled Systems.